Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894962922> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2894962922 endingPage "947A" @default.
- W2894962922 startingPage "947A" @default.
- W2894962922 abstract "SESSION TITLE: Systemic Disease and the Lung 2 SESSION TYPE: Original Investigations PRESENTED ON: 10/10/2018 02:30 PM - 03:30 PM PURPOSE: Ruxolitinib is a selective Janus kinase inhibitor that primarily inhibits JAK1 and JAK2 mediated cytokine signaling and growth factors involved with immune function and hematopoiesis. Ruxolitinib has shown promise in corticosteroid-refractory graft-versus-host disease (GVHD). We hypothesized that ruxolitinib would be an effective steroid sparing agent in bronchiolitis obliterans syndrome (BOS) as a manifestation of GVHD. METHODS: Twelve patients with a diagnosis of BOS and a significant reduction in forced expiratory volume in 1 second (FEV1) after hematopoietic stem cell transplantation (HSCT) were treated with ruxolitinib. Their daily average dosing of prednisone was followed in addition to their FEV1 for a period of 3-6 months following initiation of ruxolitinib. RESULTS: Following ruxolitinib initiation, there was significant reduction in daily average prednisone dosing from an average of 23.9 mg per day to 12.9 mg per day (46% percent reduction) over 3-6 months. Additionally, when FEV1 was reevaluated in the same time period, 7 patients improved, 1 stayed the same, and only 4 continued to have decreasing function. All 12 patients were alive at 1 year follow-up. CONCLUSIONS: Ruxolitinib is safe and a potential option as a steroid sparing agent in BOS after HSCT. It should be considered as a treatment option in those patients and may help improve or stabilize lung function in addition to reducing steroid requirements. CLINICAL IMPLICATIONS: Ruxolitinib appears to reduce steroid requirements in BOS after HSCT and may also improve or stabilize lung function. DISCLOSURES: No relevant relationships by Kyle Brownback, source=Web Response No relevant relationships by Faizan Shaikh, source=Web Response No relevant relationships by Christopher Streiler, source=Web Response" @default.
- W2894962922 created "2018-10-12" @default.
- W2894962922 creator A5049629429 @default.
- W2894962922 creator A5060558343 @default.
- W2894962922 creator A5082673497 @default.
- W2894962922 date "2018-10-01" @default.
- W2894962922 modified "2023-09-26" @default.
- W2894962922 title "EFFECT OF RUXOLITINIB AS A STEROID SPARING AGENT IN BRONCHIOLITIS OBLITERANS SYNDROME DUE TO GRAFT VS HOST DISEASE" @default.
- W2894962922 doi "https://doi.org/10.1016/j.chest.2018.08.852" @default.
- W2894962922 hasPublicationYear "2018" @default.
- W2894962922 type Work @default.
- W2894962922 sameAs 2894962922 @default.
- W2894962922 citedByCount "0" @default.
- W2894962922 crossrefType "journal-article" @default.
- W2894962922 hasAuthorship W2894962922A5049629429 @default.
- W2894962922 hasAuthorship W2894962922A5060558343 @default.
- W2894962922 hasAuthorship W2894962922A5082673497 @default.
- W2894962922 hasConcept C126322002 @default.
- W2894962922 hasConcept C141071460 @default.
- W2894962922 hasConcept C2776112149 @default.
- W2894962922 hasConcept C2776739411 @default.
- W2894962922 hasConcept C2777408962 @default.
- W2894962922 hasConcept C2778720950 @default.
- W2894962922 hasConcept C2779972918 @default.
- W2894962922 hasConcept C2780007613 @default.
- W2894962922 hasConcept C2780076729 @default.
- W2894962922 hasConcept C2781448352 @default.
- W2894962922 hasConcept C2911091166 @default.
- W2894962922 hasConcept C71924100 @default.
- W2894962922 hasConcept C90924648 @default.
- W2894962922 hasConceptScore W2894962922C126322002 @default.
- W2894962922 hasConceptScore W2894962922C141071460 @default.
- W2894962922 hasConceptScore W2894962922C2776112149 @default.
- W2894962922 hasConceptScore W2894962922C2776739411 @default.
- W2894962922 hasConceptScore W2894962922C2777408962 @default.
- W2894962922 hasConceptScore W2894962922C2778720950 @default.
- W2894962922 hasConceptScore W2894962922C2779972918 @default.
- W2894962922 hasConceptScore W2894962922C2780007613 @default.
- W2894962922 hasConceptScore W2894962922C2780076729 @default.
- W2894962922 hasConceptScore W2894962922C2781448352 @default.
- W2894962922 hasConceptScore W2894962922C2911091166 @default.
- W2894962922 hasConceptScore W2894962922C71924100 @default.
- W2894962922 hasConceptScore W2894962922C90924648 @default.
- W2894962922 hasIssue "4" @default.
- W2894962922 hasLocation W28949629221 @default.
- W2894962922 hasOpenAccess W2894962922 @default.
- W2894962922 hasPrimaryLocation W28949629221 @default.
- W2894962922 hasRelatedWork W2019250368 @default.
- W2894962922 hasRelatedWork W2320341162 @default.
- W2894962922 hasRelatedWork W2344986991 @default.
- W2894962922 hasRelatedWork W2894962922 @default.
- W2894962922 hasRelatedWork W2913640804 @default.
- W2894962922 hasRelatedWork W2972076846 @default.
- W2894962922 hasRelatedWork W3039265579 @default.
- W2894962922 hasRelatedWork W3173258610 @default.
- W2894962922 hasRelatedWork W4251383394 @default.
- W2894962922 hasRelatedWork W4283819316 @default.
- W2894962922 hasVolume "154" @default.
- W2894962922 isParatext "false" @default.
- W2894962922 isRetracted "false" @default.
- W2894962922 magId "2894962922" @default.
- W2894962922 workType "article" @default.